Drugs & Targets Wistar, Accelerated Biosciences collaborate to develop immune cell therapies July 12, 2024Vol.50 No.28
JudiciaryNews Analysis Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care July 05, 2024Vol.50 No.27By Matthew Bin Han Ong
Conversation with The Cancer Letter Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside July 05, 2024Vol.50 No.27By Matthew Bin Han Ong
Guest EditorialSatire A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supplyWarning: This is not a public health recommendation. Do not implement. July 05, 2024Vol.50 No.27By Michael A. Friedman
Cancer History ProjectGuest Editorial At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago July 05, 2024Vol.50 No.27By Katerina A. Politi and Roy S. Herbst
In Brief Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center July 05, 2024Vol.50 No.27
In Brief Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office July 05, 2024Vol.50 No.27
In Brief Marjan Boerma invested in J. Thomas May Distinguished Endowed Chair in Oncology at UAMS July 05, 2024Vol.50 No.27
